GB004 (formerly AKB-4924) for the treatment of IBD
GB004, a gut-targeted, small molecule HIF-1 alpha stabilizer, is being developed for the treatment of inflammatory bowel disease (IBD). Unlike other HIF stabilizers that mainly affect HIF-2 alpha and stimulate erythropoiesis, GB004 is differentiated in that it preferentially stabilizes HIF-1 alpha which has a profound anti-inflammatory and mucosal healing effect. We believe these properties make it an ideal candidate for the treatment of IBD. Gossamer Bio recently completed a Phase 1b study in patients with ulcerative colitis and is planning a Phase 2 study.